Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

NCT04246723 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis c Genotype 1

Interventions

DRUG: Narlaprevir
DRUG: Ritonavir
DRUG: Sofosbuvir

Sponsor

R-Pharm

Collaborators

[object Object]
[object Object]
[object Object]